Get the Stockscreener App
1.94
0.00%
0.00
Intensity Therapeutics Inc stock is traded at $1.94, with a volume of 7,568.
It is up +0.00% in the last 24 hours and down -13.00% over the past month.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
See More
Previous Close:
$1.94
Open:
$1.84
24h Volume:
7,568
Relative Volume:
0.24
Market Cap:
$29.45M
Revenue:
-
Net Income/Loss:
$-16.26M
P/E Ratio:
-1.6421
EPS:
-1.1814
Net Cash Flow:
$-13.50M
1W Performance:
-1.02%
1M Performance:
-13.00%
6M Performance:
-41.65%
1Y Performance:
-57.46%
1-Day Range:
$1.83
$1.99
1-Week Range:
$1.80
$1.99
52-Week Range:
$1.50
$5.275
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
1.94 | 29.45M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.49 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.39 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
546.22 | 33.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
226.28 | 29.29B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
208.31 | 22.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Intensity Therapeutics Inc Stock (INTS) Latest News
IntercontinentalExchange price target lowered to $230 from $237 at BofA - Yahoo Finance
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Why Iridium Communications (IRDM) is a Top Value Stock for the Long-Term - Yahoo Finance
Soft Tissue Sarcoma Treatment Market Size in 7MM is expected - openPR.com
Insiders At Cencora Sold US$16m In Stock, Alluding To Potential Weakness - Yahoo Finance
Leading Factor Driving the Burkitt Lymphoma Therapeutics Market in 2025: Impact Of Rising HIV Incidence On ... - WhaTech
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Soft Tissue Sarcoma Clinical Pipeline | 70+ Companies Driving Innovation in Treatment - openPR
Benchmark maintains Speculative Buy on Intensity Therapeutics By Investing.com - Investing.com South Africa
Benchmark maintains Speculative Buy on Intensity Therapeutics - Investing.com
Soft Tissue Neoplasms Treatment Market Size in 7MM is expected - openPR
Here is Why Growth Investors Should Buy Cencora (COR) Now - Yahoo Finance
Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment - Yahoo Finance
INTENSITY THERAPEUTICS Earnings Results: $INTS Reports Quarterly Earnings - Nasdaq
Small Number of Acne Products Recalled for Problematic Levels of Benzene - 69News WFMZ-TV
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update - Longview News-Journal
Intensity Therapeutics Doubles R&D Investment as Cancer Trials Gain Momentum - Stock Titan
Tempest Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:TPST - Benzinga
Bile Duct Neoplasms Treatment Market Size Report 2032 | Taewoong - openPR.com
Alpheus Medical Publishes Promising Early Clinical Results of Sonodynamic Therapy for the Treatment of Newly Diagnosed Glioblastomas - BioSpace
Equillium (NASDAQ:EQ) Stock Quotes, Forecast and News Summary - Benzinga
Thyroid Cancer Market Size to Reach USD 1,892.4 Million by 2035, Impelled by Advancements in Gene Therapy and Personalized Medicine - BioSpace
Grafapex Approved for Reduced-Intensity Stem Cell Transplants in AML and MDS Patients - Managed Healthcare Executive
Intensity Infrastucture Partners Launches Open Season for New Natural Gas Transmission Pipeline to Serve the Bakken Region - Yahoo Finance
Clinical Trials News Live Feed - StockTitan
Xylem (XYL) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Drug Monitoring Committee Authorizes Continuation of Intensity T - GuruFocus.com
Intensity Therapeutics' sarcoma trial proceeds after review By Investing.com - Investing.com Canada
Intensity Therapeutics' sarcoma trial proceeds after review - Investing.com India
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review - Nasdaq
High Intensity Focused Ultrasound Market Forecast and Company Analysis 2025-2033 Featuring Koninklijke Philips, Johnson & Johnson, Hitachi, General Electrics, Medtronic, Stryker, EDAP TMS, Theraclion - Yahoo Finance
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.35%
10.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):